Joshua A. Kazam
Director · Allogene Therapeutics, Inc.
Individual
- 2025
- Jun 23, 2026
- 3
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Joshua A. Kazam files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- David D. Chang - $289K in ALLO purchases and sales in the last 12 months
- Zachary Roberts - $104K in ALLO purchases and sales in the last 12 months
- Earl Martin Douglas - $103K in ALLO purchases and sales in the last 12 months
- Geoffrey M. Parker - $88K in ALLO purchases and sales in the last 12 months
- Benjamin Machinas Beneski - $52K in ALLO purchases and sales in the last 12 months
- Annie Yoshiyama - $29K in ALLO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Joshua A. Kazam?
Joshua A. Kazam is a corporate insider, tracked as Director of Allogene Therapeutics, Inc. (ALLO). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Joshua A. Kazam last file a Form 4?
The most recent primary Form 4 on record is dated 23 June 2026, one of 3 filings going back to 2025.
